Patents

Mirus Bio receives broad RNAi patent using hydrodynamic intravascular injection

Published in Lab Law Weekly, January 12th, 2007

Mirus Bio Corporation announced the grant of U.S. Patent No.7,148,205 titled "Intravascular Delivery of Non-Viral Nucleic Acid," which broadly covers administration of RNAi-inducing molecules via hydrodynamic intravascular injection.

A key bottleneck impeding the progress of the groundbreaking field of RNA interference (RNAi) has been the lack of effective delivery methods. This delivery breakthrough combined with RNAi creates a powerful discovery research tool for studying gene function in animal models, and in the long term might be used for certain human therapeutic tissues.

Hydrodynamic intravascular injection is a method to deliver nucleic acids...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry